TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3

Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia

(2015) Xin Long et al.   BRITISH JOURNAL OF HAEMATOLOGY

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

(2015) Ignacio Garrido-Laguna et al.   Nature Reviews Clinical Oncology

The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2

(2015) Nicolas Skrypek et al.   Oncotarget

Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy

(2015) Hayato Fujita et al.   NEOPLASIA

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

(2014) Mara H. Sherman et al.   CELL

Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

(2014) Lucas de Sousa Cavalcante et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Improved vectors and genome-wide libraries for CRISPR screening

(2014) Neville E Sanjana et al.   NATURE METHODS

Molecular mechanisms of epithelial–mesenchymal transition

(2014) Samy Lamouille et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer

(2014) Milind Javle et al.   PLoS One

Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis

(2014) Zhu-Qing Liu et al.   PLoS One

Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells

(2013) Qing-Zhi Long et al.   ANTI-CANCER DRUGS

Pancreatic Stellate Cell Models for Transcriptional Studies of Desmoplasia-Associated Genes

(2013) Angela Mathison et al.   PANCREATOLOGY

Human Concentrative Nucleoside Transporter 3 Transfection with Ultrasound and Microbubbles in Nucleoside Transport Deficient HEK293 Cells Greatly Increases Gemcitabine Uptake

(2013) Robert J. Paproski et al.   PLoS One

Molecular Analysis of Precursor Lesions in Familial Pancreatic Cancer

(2013) Tatjana Crnogorac-Jurcevic et al.   PLoS One

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

(2013) A. Neesse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

(2013) Ophir Shalem et al.   SCIENCE

MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes

(2013) S Nath et al.   Oncogenesis

Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma

(2012) Hao Xie et al.   CANCER

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance

(2012) Mert Erkan et al.   CURRENT MOLECULAR MEDICINE

Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations

(2012) Maha Elnaggar et al.   CURRENT PHARMACEUTICAL DESIGN

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

(2012) Raphaël Maréchal et al.   GASTROENTEROLOGY

CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells

(2011) Kwang-Beom Lee et al.   CANCER LETTERS

The Matricellular Protein Cysteine-rich Protein 61 (CCN1/Cyr61) Enhances Physiological Adaptation of Retinal Vessels and Reduces Pathological Neovascularization Associated with Ischemic Retinopathy

(2011) Adeel Hasan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis

(2011) Inamul Haque et al.   Molecular Cancer

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets

(2011) Joon-Il Jun et al.   NATURE REVIEWS DRUG DISCOVERY

Precursor lesions in pancreatic cancer: morphological and molecular pathology

(2011) Christopher J. Scarlett et al.   PATHOLOGY

Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma

(2009) R. Marechal et al.   CLINICAL CANCER RESEARCH

Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression

(2008) R. F. Hwang et al.   CANCER RESEARCH

Cysteine-Rich Protein 61 and Connective Tissue Growth Factor Induce Deadhesion and Anoikis of Retinal Pericytes

(2008) Haibo Liu et al.   ENDOCRINOLOGY